Opening book details…
Can I read Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations on EtoBox?
Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations by Payam Tabarsi; Nassim Anjidani; Ramin Shahpari; Masoud Mardani; Araz Sabzvari; Babak Yazdani; Khashayar Roshanzamir; Behnam Bayatani; Ali Taheri; Nikolai Petrovsky; Lei Li; Saghar Barati is a Medicine article available to read on EtoBox.
What is Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations about?
Objective: We aimed to investigate the immunogenicity and safety of SpikoGen®, a subunit COVID-19 vaccine composed of a recombinant prefusion-stabilized SARS-CoV-2 spike protein combined with the Advax-CpG55.2TM adjuvant, in seronegative and seropositive populations as primary vaccination. Methods: This randomized, placebo-controlled, double-blind phase 2 trial was conducted on 400 participants randomized 3:1 to receive two doses of 25 mg of SpikoGen® 3 weeks apart or the placebo. The primary safety outcomes were the incidence of solicited adverse events up to 7 days after each dose and unsolicited adverse events up to 28 days after the second dose. The primary immunogenicity outcomes were seroconversion against the S 1 protein and the geometric mean concentration of S 1 antibodies by days 21 and 35. Results: The SpikoGen® vaccine was well tolerated and no serious adverse events were recorded. The most common solicited adverse events were injection site pain and fatigue, largely graded as mild and transient. By day 35 (2 weeks post second dose), the seroconversion rate against S 1 was 63.55 (95% CI: 57.81e69.01) in the SpikoGen® group versus 7.23 (95% CI: 2.7e15.07) in the placebo
Who reads Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Payam Tabarsi; Nassim Anjidani; Ramin Shahpari; Masoud Mardani; Araz Sabzvari; Babak Yazdani; Khashayar Roshanzamir; Behnam Bayatani; Ali Taheri; Nikolai Petrovsky; Lei Li; Saghar Barati
- Publisher
- Elsevier BV
- Published
- 2022
- Language
- EN
- Field
- Medicine (Health Sciences)